Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kfar Saba
Clinical trial register · Israel

Clinical Trials in Kfar Saba, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Israel and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2438 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2438
Studies in scope
all four open statuses
1243
Recruiting now
open to new participants
461
Lead sponsors
across recruiting studies
Top sites
Haifa 94 Ramat Gan 86 Jerusalem 80 Petah Tikva 63 Tel Aviv 52
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca39 Merck Sharp & Dohme LLC28 Eli Lilly and Company19 Meir Medical Center17 Janssen Research & Development, LLC17 Clear sponsor filter
Site location
Haifa94 Ramat Gan86 Jerusalem80 Petah Tikva63 Tel Aviv52
All 24 locations
Target enrolment
to

Trials with a site in Kfar Saba

28 of 2438 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Israel
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2026-05-04
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
Jerusalem, Kfar Saba, Ramat Gan
2026-04-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Haifa, Kfar Saba, Petah Tikva, Ramat Gan
2026-04-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
996
Ashkelon, Haifa, Kfar Saba, Sakhnin
2025-11-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Beer Ya Akov, Jerusalem, Kfar Saba, Ramat Gan, Tel Aviv
2025-10-08
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Haifa, Kfar Saba, Ramat Gan, Tsrifin
2025-06-30
Recruiting
Merck Sharp & Dohme LLC
Phase 2
144
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2025-05-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Haifa, Jerusalem, Kfar Saba, Tel Aviv
2025-05-22
Recruiting
Merck Sharp & Dohme LLC
Phase 2
96
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2025-05-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin
2025-05-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
Haifa, Holon, Jerusalem, Kfar Saba, Safed
2025-04-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Hadera, Haifa, Jerusalem, Kfar Saba, Ramat Gan
2025-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 2
90
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2025-03-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Haifa, Jerusalem, Kfar Saba, Ramat Gan
2024-10-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Hadera, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Sakhnin, Tsrifin
2024-08-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Afula, Ashkelon, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Afula, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Afula, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2023-12-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Afula, Ashkelon, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2023-10-25
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Haifa, Jerusalem, Kfar Saba, Ramat Gan
2021-12-17
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
110
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2021-08-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
815
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2021-05-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin
2021-04-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
6,033
Kfar Saba, Tel Aviv, Haifa, Jerusalem
2020-02-27
Recruiting
Merck Sharp & Dohme LLC
Observational
1,065
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2019-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
450
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2019-12-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2019-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Afula, Ashdod, Beersheba, Haifa, Jerusalem, Kfar Saba, Nazareth, Petah Tikva
2018-12-27
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Israeli investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-israel/city/kfar-saba

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Israel and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,438 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies with a site in Kfar Saba that also match the filters currently applied.

How many clinical trials are recruiting in Kfar Saba?

18 of the 28 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kfar Saba), 28 studies
PhaseStudiesRecruitingShare
Phase 3191167.9%
Phase 24314.3%
Phase 1/23210.7%
Observational113.6%
Phase 1113.6%

Most active sponsors

Lead sponsors with the most studies (Kfar Saba)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC2818
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.